Genentech’s Mellman: Moral Conflict On PD-L1 Testing Is “Red Herring”
Executive Summary
The argument that PD-L1-negative patients might be unfairly deprived of treatment is a red herring that recalls “really old-school drug development,” says Genentech cancer immunotherapy head exec Ira Mellman.